https://www.selleckchem.com/pr....oducts/sar439859.htm
To assess the utility of globotriaosylsphingosine (lyso-Gb ) for clinical monitoring of treatment response in patients with Fabry disease receiving migalastat. A post hoc analysis evaluated data from 97 treatment-naive and enzyme replacement therapy (ERT)-experienced patients with migalastat-amenable GLA variants from FACETS (NCT00925301) and ATTRACT (NCT01218659) and subsequent open-label extension studies. The relationship between plasma lyso-Gb and measures of Fabry disease progression (left ventricular mass index [LVMi], estimated
Like
Comment
Share
